AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00861666 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Forgiveness-Based Writing
Description: Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task.
Study NCT01793753 — intervention group
Intervention type: DRUG
Intervention: Propofol
Study NCT04576728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimodulin
Description: IMP will be administered via IV infusion on 5 consecutive days.
Study NCT04576728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (human albumin 1%)
Description: IMP will be administered via IV infusion on 5 consecutive days.
Study NCT04368507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYB101
Description: 1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity~2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity
Study NCT03629769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxelan
Description: Administration of one suppository of proxelan once a day for 30 days
Study NCT01704807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: foot orthotics
Description: Experimental wore experimental orthotics throughout the study period as much of the day as possible.
Study NCT01704807 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham foot orthotic
Description: Control group wore sham insoles as much of the time as possible for the duration of the study period.
Study NCT03832647 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Epiduo
Description: 100 per arm Adapalene/ Benzoyl Peroxide
Study NCT03832647 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epiduo
Description: 100 per arm Adapalene/ Benzoyl Peroxide
Study NCT03832647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salicylic Acid
Description: Salicylic Acid
Study NCT03832647 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydréane légère
Description: moisturizer
Study NCT01137513 — intervention group
Intervention type: DEVICE
Intervention: Observational Measurement of T-wave Alternans
Description: Measurement is similar to typical EKG
Study NCT01137513 — intervention group
Intervention type: DEVICE
Intervention: T-wave Alternans
Description: T-Wave Alternans will be measured in an observational fashion
Study NCT01062308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taping and Sham Taping
Description: Taping shoulder with Hospiplast tape.~Taping the shoulder after acute stroke to prevent shoulder injury and pain.~Taping the shoulder after acute stroke and compare with sham taping group.~Treatments:~1. Positioning technique~2. Handling technique~3. Range of motion exercises~4. Taping technique
Study NCT03451019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Hydrochloride
Description: Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal
Study NCT01062308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Taping
Description: Shoulder Taping for 14 days which will be changed after every 3 days.
Study NCT00251134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zodin (drug)
Description: 1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months
Study NCT00251134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil (placebo)
Description: 1 gram olive oil daily for a period of 12 months
Study NCT00657423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treated by endostar combined with docetaxel and cisplatin
Description: recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
Study NCT00657423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treated by docetaxel and cisplatin
Description: docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
Study NCT01804088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula™ 535 Iliac Balloon-Expandable Stent
Description: Treatment of symptomatic vascular disease of the iliac arteries
Study NCT03451019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Single oral doses of lanthanum (1000 mg)
Study NCT05826873 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Discharge antibiotic stewardship intervention
Description: Hospitalists will be provided with group-level, quarterly feedback reports illustrating the number of prescriptions that had the appropriate antibiotic duration and appropriate antibiotic choice for each of the three conditions.
Study NCT03488693 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Radiotherapy given
Study NCT03113370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish Oil capsules
Study NCT03113370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive Oil
Study NCT03488693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Radiation
Description: No radiotherapy given
Study NCT02728739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiogram (TTE) Assesment
Description: Transthoracic Echocardiogram (TTE) will be carried out on all heart failure patients with elevated BNP level (>30 pg/ ml) for grading of MR severity within 7 days.
Study NCT00461981 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV, Trivalent Inactivated Influenza Virus Vaccine
Description: 0.25 mL will be administered intramuscularly for each of two doses
Study NCT00461981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist, Influenza Virus Vaccine Live
Description: 0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
Study NCT03526653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise without visual stimuli
Description: exercise on an ergometer or motomed in an environment without other visual stimuli
Study NCT03526653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: excercise with National Geografics
Description: exercise on an ergometer or motomed while watching the National Geografics channel on television
Study NCT03526653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise with MemoRide
Description: excercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
Study NCT00448201 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-thymocyte globulin
Description: 0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)
Study NCT00448201 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Description: GM-CSF 500 ug everyday (QD) subcutaneously will be given to recipients who remain with an Absolute neutrophil count (ANC) \< 1000/microliter (uL) past day 20
Study NCT00448201 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic allogeneic lymphocytes
Description: A minimum total cluster of differentiation 34 (CD34)+ cell dose of 3 x 10\^6 cells/kg and a maximum 8 x 10\^6 cells/kg will be infused on day 0
Study NCT00448201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: busulfan
Description: 6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
Study NCT00448201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Description: fludarabine 30 mg/m\^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3
Study NCT00448201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate 5 mg/m\^2 per day on days +1, +3 and +6
Study NCT00448201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
Study NCT00448201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0
Study NCT00448201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0
Study NCT02993861 — intervention group
Intervention type: OTHER
Intervention: Anti-epileptics
Study NCT02391025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 citrate
Description: Given via IV at time of imaging
Study NCT02391025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging procedure
Study NCT00632567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: caesarean section
Description: caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
Study NCT00632567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal delivery
Description: vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
Study NCT02187549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYMOVIS
Description: Intra-articular injection
Study NCT02187549 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-Articular Injection
Study NCT02370511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Description: Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
Study NCT01817075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate Skin Cleanser
Description: Given CHG cleansing
Study NCT01817075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01817075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01817075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild Soap Skin Cleanser
Description: Given control cleansing
Study NCT01817075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01817075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02288104 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: needle based confocal endomicroscopy
Description: real time imaging of living tissue at microscopic scale, through a needle.
Study NCT00970905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
Study NCT00970905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
Study NCT03976752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya
Description: Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic.
Study NCT01221636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Solution for injection, Intravenous, 750 mg, 1 day
Study NCT01221636 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept
Description: Solution for injection, Intravenous, 750 mg, 1 day
Study NCT06337604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: TNP-2092 capsules 300 mg twice daily(BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study NCT06337604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNP-2092 capsules placebo
Description: TNP-2092 Capsules Placebo 300 mg BID : Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study NCT02405819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 'My Care Plan'
Description: 'My Care Plan' is a patient-initiated survivorship care planning tool.
Study NCT02405819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 'Survivorship Care Plan Builder'
Description: 'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
Study NCT06337604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole sodium enteric-coated tablets
Description: Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study NCT06337604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium enteric-coated tablets
Description: Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
Study NCT02876289 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Study NCT01372631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miniature spectral imaging system
Description: Use of miniature spectral imaging system
Study NCT01372631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bench-top optical spectrometer
Description: Use of bench-top optical spectrometer
Study NCT01372631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High resolution microendoscope
Description: Use of high resolution microendoscope
Study NCT01234597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLARGINE (HOE901)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT01234597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (HOE901)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT01234597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLULISINE (HMR1964)
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Study NCT01234597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE (HMR1964)
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Study NCT01836562 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STEM CELL THERAPY
Description: Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
Study NCT02126215 — intervention group
Intervention type: PROCEDURE
Intervention: MRI CO2 and O2 stress testing
Description: Pre and post operatively
Study NCT01442662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib + gemcitabine
Description: pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
Study NCT00954265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10000 IU urinary HCG
Description: ovulation triggering
Study NCT00954265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mcg recombinant HCG
Description: ovulation triggering
Study NCT03021980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SuperFIT
Description: Behavioural intervention with two components. One component will consist of social and physical environmental changes at the preschools and the other component consists of a family educational program.
Study NCT00168389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
Study NCT03895359 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation
Description: For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
Study NCT03895359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization
Description: Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
Study NCT01715948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CROS hearing aid
Description: Participants were randomly assigned to be fitted with the CROS hearing aid either at the end of the first visit or at the end of the second visit. They were given a 2-week trial with the CROS and asked to refrain from wearing their BAHD during that time. At the end of the first visit, four participants were fitted with the CROS hearing aid and were subsequently tested with this device on their second visit, at which time they were instructed to use the BAHD for the next 2 weeks. This protocol was reversed in the other four participants, with testing after each device experience. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
Study NCT01715948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone-anchored hearing device (BAHD)
Description: All participants had received BAHD implantation prior to the study. They were randomly selected to continue wearing their BAHD for 2 weeks following the end of the first visit or the end of the second visit. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
Study NCT00168389 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
Study NCT01607879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care ADT + (HMB + arginine + glutamine)
Description: 1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months
Study NCT01607879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care ADT
Description: Patient will receive standard of care androgen deprivation therapy (ADT) alone
Study NCT00447668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga for back pain
Study NCT00447668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: exercises for back pain
Study NCT00447668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care book recommendations
Description: Self-care book for back pain
Study NCT04292210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perisafe
Description: A medical device simplifying the connection of tubing as well as breaking of the frangible which is done in a sterile environment with the help of levers and buttons.